HLA-G and cancer: In this study, we evaluated as follows: (i) not only the BRAFV600E mutation status, but also BRAF protein expression that has been poorly explored in PTC; (ii) the TERT promoter mutations that are widely associated with an aberrant upregulation of TERT expression and immortalization of cancer cells [24]; (iii) the immune checkpoint HLA-G molecule expression that has been associated with poor prognosis in several human cancers [12]; (iv) the modulated miRNA profile targeting these markers in PTC areas compared with non-tumoral areas.